SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C.  20549

                                   FORM 8-K
                                CURRENT REPORT

       Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                                 June 16, 1999

                                ICOS CORPORATION

Delaware                                0-19171                  91-1463450
(State or other jurisdiction of   (Commission File No.)       (I.R.S. Employer
incorporation or organization)                               Identidication No.)

22021 20th Avenue Southeast, Bothell  WA                          98021
(Address of principal executive offices)                        (Zip code)

                                   (425) 485-1900
                  (Registrant's telephone number, including area code)

<PAGE>

ITEM 5:     Other Events

The registrant issued the following press release on June 16, 1999:

ICOS Corporation (NASDAQ:ICOS) announced today the appointment of
Paul N. Clark, 52, as the company's new Chief Executive Officer and
President.  George B. Rathmann, Chairman since 1990 and CEO and
President since 1991, will continue in his role as Chairman of the
Board.  Mr. Clark has twenty-five years of experience in the pharmaceutical
industry and was most recently with Abbott Laboratories for fourteen years
before retiring in 1998.  Mr. Clark was Executive Vice President, a member
of the Board of Directors and, previous to that, was President of the
Pharmaceutical Division where he was responsible for growing Abbott's
pharmaceutical business.  His responsibilities at Abbott also included
chemical and agricultural products.  In announcing the appointment,
George B. Rathmann, Chairman of the Board of Directors for ICOS said,
"Paul brings a distinguished career in pharmaceuticals and we have had the
good fortune over the past four years to work closely with him through a
corporate collaboration with Abbott.  Paul is known and well respected
throughout ICOS and his experience is well suited to bringing the company
to the stage of commercialization."

"I am enthusiastic about joining ICOS," said Paul Clark.  "The company has
an outstanding scientific team with leaders in fields that include
inflammation and an excellent development group that is conducting numerous
clinical trials.  The company has been able to finance its operations as
necessary and has a very strong Board of Directors.  With the company's
plans to bring significant products to market, I believe my background in
the pharmaceutical industry can add value.  It will be a privilege to work
with George Rathmann who has contributed so much to ICOS and the biotech
industry."

ICOS is discovering and developing new pharmaceuticals by seeking points of
intervention in the inflammatory process that may lead to more specific
and efficacious drugs.  The Company's research and drug development
programs involve both acute and chronic conditions such as acute
respiratory distress syndrome, hemorrhagic shock, ischemic stroke,
myocardial infarction, erectile dysfunction, pancreatitis and psoriasis.

ITEM 7:    Financial Statements, Pro Forma Financial Information and Exhibits
    (c)    See Exhibit Index

<PAGE>

                               INDEX TO EXHIBITS
                                                                     Page
20.1       Press release issued June 16, 1999                          #




---------------------
# Filed with this document

<PAGE>

                                   SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
ubdersigned thereunto duly authorized.

                                                 ICOS Corporation

Date:  June 16, 1999                             By:/S/ HOWARD S. MENDELSOHN
--------------------                                ------------------------
                                                    Howard S. Mendelsohn
                                                    Chief Accounting Officer

<PAGE>
[{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 4140}]
{"company-data": {"conformed-name": "ICOS CORP / DE", "cik": "0000874294", "assigned-sic": "2834", "irs-number": "911463450", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19171", "film-number": "99650743"}, "business-address": {"street1": "22021-20TH AVENUE S.E.,", "city": "BOTHELL", "state": "WA", "zip": "98021", "phone": "2064851900"}, "mail-address": {"street1": "22021 20TH AVE SE", "city": "BOTHELL", "state": "WA", "zip": "98021"}}
SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C.  20549

                                   FORM 8-K
                                CURRENT REPORT

       Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                                 June 16, 1999

                                ICOS CORPORATION

Delaware                                0-19171                  91-1463450
(State or other jurisdiction of   (Commission File No.)       (I.R.S. Employer
incorporation or organization)                               Identidication No.)

22021 20th Avenue Southeast, Bothell  WA                          98021
(Address of principal executive offices)                        (Zip code)

                                   (425) 485-1900
                  (Registrant's telephone number, including area code)
ITEM 5:     Other Events

The registrant issued the following press release on June 16, 1999:

ICOS Corporation (NASDAQ:ICOS) announced today the appointment of
Paul N. Clark, 52, as the company's new Chief Executive Officer and
President.  George B. Rathmann, Chairman since 1990 and CEO and
President since 1991, will continue in his role as Chairman of the
Board.  Mr. Clark has twenty-five years of experience in the pharmaceutical
industry and was most recently with Abbott Laboratories for fourteen years
before retiring in 1998.  Mr. Clark was Executive Vice President, a member
of the Board of Directors and, previous to that, was President of the
Pharmaceutical Division where he was responsible for growing Abbott's
pharmaceutical business.  His responsibilities at Abbott also included
chemical and agricultural products.  In announcing the appointment,
George B. Rathmann, Chairman of the Board of Directors for ICOS said,
"Paul brings a distinguished career in pharmaceuticals and we have had the
good fortune over the past four years to work closely with him through a
corporate collaboration with Abbott.  Paul is known and well respected
throughout ICOS and his experience is well suited to bringing the company
to the stage of commercialization."

"I am enthusiastic about joining ICOS," said Paul Clark.  "The company has
an outstanding scientific team with leaders in fields that include
inflammation and an excellent development group that is conducting numerous
clinical trials.  The company has been able to finance its operations as
necessary and has a very strong Board of Directors.  With the company's
plans to bring significant products to market, I believe my background in
the pharmaceutical industry can add value.  It will be a privilege to work
with George Rathmann who has contributed so much to ICOS and the biotech
industry."

ICOS is discovering and developing new pharmaceuticals by seeking points of
intervention in the inflammatory process that may lead to more specific
and efficacious drugs.  The Company's research and drug development
programs involve both acute and chronic conditions such as acute
respiratory distress syndrome, hemorrhagic shock, ischemic stroke,
myocardial infarction, erectile dysfunction, pancreatitis and psoriasis.

ITEM 7:    Financial Statements, Pro Forma Financial Information and Exhibits
    (c)    See Exhibit Index
INDEX TO EXHIBITS
                                                                     Page
20.1       Press release issued June 16, 1999                          #

---------------------
# Filed with this document
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
ubdersigned thereunto duly authorized.

                                                 ICOS Corporation

Date:  June 16, 1999                             By:/S/ HOWARD S. MENDELSOHN
--------------------                                ------------------------
                                                    Howard S. Mendelsohn
                                                    Chief Accounting Officer